Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Zhornitsky, Simon ^a   Johnson, Trina A ^a   Metz, Luanne M ^a   Weiss, Samuel ^a   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Experimental autoimmune encephalomyelitis; Interferon ; Multiple sclerosis; Prolactin

Indexed keywords

PROLACTIN; RECOMBINANT BETA INTERFERON; BETA INTERFERON; IMMUNOLOGIC FACTOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; LEUKOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MORNING DOSAGE; MOUSE; NONHUMAN; POST HOC ANALYSIS; SPLEEN CELL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; MULTIPLE SCLEROSIS; PATHOLOGY; SPINAL CORD; TIME FACTOR;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; PROLACTIN; SPINAL CORD; TIME FACTORS;

EID: 84925280673     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0278-8     Document Type: Article

References (29)

1. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180-8.
2. Draca S, Lević Z. The possible role of prolactin in the immunopathogenesis of multiple sclerosis. Med Hypotheses. 1996;47:89-92.
3. Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler. 2013;19:15-23.
4. Ghezzi A, Caputo D. Pregnancy: a factor influencing the course of multiple sclerosis? Eur Neurol. 1981;20:115-7.
5. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339:285Y291.
6. Paavilainen T, Kurki T, Färkkilä M, Salonen O, Parkkola R, Airas L. Lower brain diffusivity in postpartum period compared to late pregnancy: results from a prospective imaging study of multiple sclerosis patients. Neuroradiology. 2012;54:823Y828.
7. Ponsonby AL, Lucas RM, van der Mei IA, Dear K, Valery PC, Pender MP, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event. The AusImmune Study. Neurology. 2012;78:867Y874.
8. Castracane DV, Gimpel T. Reference values in pregnancy for IMMULITE assays. Technical report. Los Angeles: DPC; 2000.
9. Nelson RF. An introduction to behavioral endocrinology, vol. 4th. Sunderland, Mass: Sinauer Associates Inc; 2011. ISBN 0-87893-620-3.
10. Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012;259:2246Y2248.
11. Langer-Gould A, Hellwig K. One can prevent post-partum MS relapses by exclusive breast feeding: yes. Mult Scler. 2013;19:1567-8.
12. Langer-Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66:958Y963.
13. Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW, et al. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci. 2007;27:1812-23.
14. Correale J, Farez MF, Ysrraelit MC. Role of prolactin in B cell regulation in multiple sclerosis. J Neuroimmunol. 2014;269:76-86.
15. Legorreta-Haquet MV, Chávez-Rueda K, Montoya-Díaz E, Arriaga-Pizano L, Silva-García R, Chávez-Sánchez L, et al. Prolactin down-regulates CD4+CD25hiCD127low/- regulatory T cell function in humans. J Mol Endocrinol. 2012;48:77-85.
16. Nagy E, Berczi I, Wren GE, Asa SL, Kovacs K. Immunomodulation by bromocriptine. Immunopharmacology. 1983;6:231-43.
17. Riskind PN, Massacesi L, Doolittle TH, Hauser SL. The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol. 1991;29:542-7.
18. Canonico PL, Sortino MA, Favit A, Aleppo G, Scapagnini U. Dihydroergocryptine protects from acute experimental allergic encephalomyelitis in the rat. Funct Neurol. 1993;8:183-8.
19. Dijkstra CD, van der Voort ER, De Groot CJ, Huitinga I, Uitdehaag BM, Polman CH, et al. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology. 1994;19:135-42.
20. Costanza M, Musio S, Abou-Hamdan M, Binart N, Pedotti R. Prolactin is not required for the development of severe chronic experimental autoimmune encephalomyelitis. J Immunol. 2013;191:2082-8.
21. Goncalves DaSilva A, Yong VW. Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am J Pathol. 2009;174:898-909.
22. Weaver A, Goncalves da Silva A, Nuttall RK, Edwards DR, Shapiro SD, Rivest S, et al. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J. 2005;19:1668-70.
23. Möderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE, et al. Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007;145:963-73.
24. Sandi C, Cambronero JC, Borrell J, Guaza C. Mutually antagonistic effects of corticosterone and prolactin on rat lymphocyte proliferation. Neuroendocrinology. 1992;56:574-81.
25. Postel-Vinay MC, de Mello CV, Gagnerault MC, Dardenne M. Growth hormone stimulates the proliferation of activated mouse T lymphocytes. Endocrinology. 1997;138:1816-20.
26. Bissay V, De Klippel N, Herroelen L, Schmedding E, Buisseret T, Ebinger G, et al. Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol. 1994;17:473-6.
27. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain Behav Immun. 2010;24:525-8.
28. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 1997;16:6926-35.
29. Bouchard B, Ormandy CJ, Di Santo JP, Kelly PA. Immune system development and function in prolactin receptor-deficient mice. J Immunol. 1999;163:576-82.